F. Hoffmann-La Roche Ltd: Early treatment with Roche's OCREVUS leads to reduced disease progression and healthcare costs; nine-year safety data reinforce favourable benefit-risk profile

77% of early-stage relapsing-remitting multiple sclerosis (RRMS) patients who had not received prior treatment achieved no evidence of disease activity (NEDA) at two years Initiation of OCREVUS as first-line

Related Keywords

Japan ,United States ,Switzerland ,America ,Levi Garraway ,Sabine Borngr ,Gerard Tobin ,Bruno Eschli ,Birgit Masjost ,Sileia Urech ,Loren Kalm ,Karsten Kleine ,Nathalie Altermatt ,Genentech ,Roche Group ,Research In Multiple Sclerosis ,Head Of Global Product Development ,Roche Group Media Relations ,European Committee For Treatment ,European Committee ,Multiple Sclerosis ,Chief Medical Officer ,Global Product ,Expanded Disability Status Scale ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,Hoffmann ,Oche ,Early ,Treatment ,Ocrevus ,Heads ,Educed ,Disease ,Progression ,Healthcare ,Costs ,Line ,Ear ,Safety ,Data ,Reinforce ,Unfavourable ,Benefit ,Risk ,Profile ,